Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate

Autor: Claudio Verzura, A. Ballerini, Anna Comparelli, Francesca Splendori, Antonio Francomano, Iginia Mancinelli, Francesco Saverio Mennini, Sergio De Filippis, Giada Trovini, Maurizio Pompili, Dario Carrus, Serena Sorice, Roberto Brugnoli, Antonio Del Casale, Giuseppe Ducci, Paolo Girardi, Gabriele Sani, Georgios D. Kotzalidis, Andrea Marcellusi, Chiara Rapinesi
Rok vydání: 2017
Předmět:
Adult
Male
medicine.medical_specialty
aripiprazole monohydrate
global assessment of functioning
long-acting injectable antipsychotics
paliperidone palmitate
schizoaffective disorder
schizophrenia
neurology
neurology (clinical)
psychiatry and mental health
pharmacology (medical)
Global Assessment of Functioning
Aripiprazole
Schizoaffective disorder
Pharmacy
Outcome Assessment (Health Care)
03 medical and health sciences
Young Adult
0302 clinical medicine
Internal medicine
Outcome Assessment
Health Care
Paliperidone Palmitate
medicine
Humans
Pharmacology (medical)
Antipsychotic Agents
Delayed-Action Preparations
Female
Middle Aged
Psychotic Disorders
Schizophrenia
business.industry
medicine.disease
030227 psychiatry
Psychiatry and Mental health
Neurology
Settore SECS-P/03 - Scienza delle Finanze
Chronic schizophrenia
Neurology (clinical)
business
030217 neurology & neurosurgery
Diagnosis of schizophrenia
medicine.drug
Zdroj: Human psychopharmacology. 33(3)
ISSN: 1099-1077
Popis: BACKGROUND Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. METHOD Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two groups (PAL and ARI treatments). We assessed global functioning, amount of oral medications, adherence to oral treatment, and number of hospitalisations before LAI introduction and at assessment time point. RESULTS Longer treatment time with LAIs (p
Databáze: OpenAIRE
Externí odkaz: